Cell>Point LLC
The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG scans are the same as the PET/CT 18F-FDG scans.
1. To demonstrate that SPECT/CT (99mTc EC DG) is not inferior to PET/CT (18F FDG PET/CT) for sensitivity or specificity measures when image interpretation of primary and metastatic lesions are compared against a truth standard in patients with a high likelihood of lung cancer. 2. To expand the patient safety experience using 99mTc EC DG.
Inclusion Criteria: 1. The subject is a male or female patient at least 18 years old. 2. The subject must agree at the time of enrollment to have the following procedures: * A tissue diagnosis of the primary lesion either prior to enrollment or within 15 days of the PET/CT study but before initiation of therapy * A SPECT/CT procedure * A baseline DCCT scan * A whole-body bone scan * A follow-up focused DCCT scan (if indicated) 3. The patient has had a non incisional biopsy demonstrating definitive evidence for lung cancer OR have clinical evidence and CT scan results consisten…
One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
Single injection of 18 F FDG range of 10-20 mCi
Arctuva estimate
Verify or correct the compensation shown for this listing.